|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
JP6647868B2
(ja)
|
2013-02-20 |
2020-02-14 |
ノバルティス アーゲー |
ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
MX2017002205A
(es)
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CA2992551A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
WO2018175636A2
(en)
*
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
US12539308B2
(en)
|
2018-01-08 |
2026-02-03 |
The Trustees Of The University Of Pennsylvania |
Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
CN109517073A
(zh)
*
|
2018-11-30 |
2019-03-26 |
北京泽勤生物医药有限公司 |
一种靶向治疗肿瘤的融合肽及其应用
|
|
WO2020122104A1
(ja)
|
2018-12-11 |
2020-06-18 |
国立大学法人京都大学 |
ゲノムｄｎａに欠失を誘導する方法
|
|
US20220160751A1
(en)
*
|
2019-04-02 |
2022-05-26 |
Yale University |
Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
|
|
SG11202111865UA
(en)
|
2019-05-01 |
2021-11-29 |
Pact Pharma Inc |
Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
|
|
KR20220051401A
(ko)
|
2019-09-06 |
2022-04-26 |
크리스퍼 테라퓨틱스 아게 |
배양 중 개선된 지속성을 갖는 유전적으로 조작된 t 세포
|
|
EP4065157A1
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
EP4076476A4
(en)
*
|
2019-12-17 |
2023-11-22 |
The General Hospital Corporation |
MODIFIED IMMUNE CELLS WITH REDUCED TOXICITY AND THEIR USES
|
|
WO2021162521A1
(ko)
*
|
2020-02-14 |
2021-08-19 |
(주)이뮤노텍바이오팜코리아 |
외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도
|
|
CN115461070A
(zh)
*
|
2020-03-18 |
2022-12-09 |
斯坦福大学托管董事会 |
组织蛋白酶抑制素基因表达的上调作为疾病的其他治疗的辅助
|
|
CA3187944A1
(en)
|
2020-06-22 |
2021-12-30 |
Ngm Biopharmaceuticals, Inc. |
Lair-1-binding agents and methods of use thereof
|
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
CN113234169B
(zh)
*
|
2020-12-11 |
2022-11-01 |
广州百暨基因科技有限公司 |
靶向cll1嵌合抗原受体及其应用
|
|
CN113045658B
(zh)
|
2020-12-11 |
2021-12-24 |
广州百暨基因科技有限公司 |
抗cll1抗体及其应用
|
|
WO2023086882A1
(en)
*
|
2021-11-11 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout
|
|
KR102521500B1
(ko)
*
|
2021-12-02 |
2023-04-14 |
한국화학연구원 |
증진된 효능을 갖는 면역세포
|
|
CN114350665A
(zh)
*
|
2022-01-19 |
2022-04-15 |
上海优替济生生物医药有限公司 |
IFN-γ抑制剂及其用途
|
|
CN114404592A
(zh)
*
|
2022-02-09 |
2022-04-29 |
复旦大学附属中山医院 |
Tet2作为靶标在治疗缺血性血管疾病中的应用
|
|
WO2024059834A2
(en)
*
|
2022-09-15 |
2024-03-21 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Downregulating inos to increase car-t killing
|
|
WO2025189025A2
(en)
*
|
2024-03-07 |
2025-09-12 |
Biontech Us Inc. |
Methods and compositions for engineering t cells
|